Cyclical or compounder: two ways to read a stock
2026-07-06 · By Lubin Danilo, founder of Lubin Investment
Analyze a stock on Lubin Investment
A compounder grows its sales and cash almost every year, with regularity. A cyclical swings between fat years and lean years following a market cycle it doesn't control, even if it ends up profitable over time. Confusing the two distorts the reading of a single figure, like valuation, and can turn a good deal into a trap, or the reverse.
- A compounder (Roper Technologies, for example) grows sales, cash, and profits steadily, year after year, with little dependence on an external market cycle.
- A cyclical (Micron, for example) depends on a market cycle it doesn't control: its sales and cash can double then halve within a few quarters depending on its product's price.
- A single isolated figure, like valuation, can lie about a cyclical: at the top of the cycle, cash generated is artificially high, which makes the stock look falsely cheap.
- Both profiles can score well in my method's quality criteria, but I never read them the same way.
- The right question about a cyclical isn't only today's price, but where we stand in the cycle.
Why I never judge two companies the same way
Take two companies my method rates as good quality: Roper Technologies and Micron. On paper, both pass most of my financial criteria. But if you analyze them through the same lens without distinction, you'll get one of them wrong, almost for sure. The reason: they don't belong to the same family of businesses. Roper is what I call a compounder. Micron is a cyclical. This distinction isn't part of the ten criteria I score, but it completely changes how I interpret each one's results and valuation.
The compounder: growth that repeats, year after year
Roper Technologies owns and operates dozens of small niche software and industrial equipment businesses, each with recurring revenue and a dominant position in its market. Result: Roper's sales grow 12.1% a year, its earnings per share 10.9% a year, almost without a hiccup from one year to the next. Return on invested capital (the cash generated by every dollar reinvested into the business) reaches 25.8%, a stable level that doesn't depend on an external market factor. That's the signature of a compounder: a machine that turns cash into more cash, predictably, quarter after quarter. A compounder's valuation is easier to judge: today's P/FCF (15.7 times for Roper) reasonably reflects its trajectory tomorrow, because that trajectory doesn't vary much.
The cyclical: growth that comes and goes with a market cycle
Micron manufactures DRAM and NAND memory, a product whose selling price can double or be cut in half within a few quarters depending on the global balance between supply and demand. Right now, demand for high speed memory for artificial intelligence (HBM memory) is pushing Micron's prices and margins up: its sales grow 17.1% a year and its cash profitability reaches 27.7%, impressive figures. But Micron's history also shows years when free cash flow turned negative, when the memory market was oversupplied. The same business can therefore produce, just a few years apart, exceptional profitability or a cash loss, without the company's underlying quality having changed: it's the cycle that turned, not the company.
The P/FCF trap on a cyclical
This is where confusion turns dangerous. P/FCF (price to free cash flow) compares a stock's price to the cash it generated over the past twelve months. On a compounder, this figure is reliable, because last year's cash resembles this year's and next year's. On a cyclical at the top of its cycle, like Micron today, this figure can become misleading in both directions: if the cash generated is artificially high because of exceptionally elevated memory prices, a P/FCF that looks cheap can actually deteriorate sharply once the cycle turns. Micron currently trades at 45 times its trailing twelve month free cash flow, a figure to read with caution: it depends heavily on how long this cycle peak holds.
| Criterion | Roper Technologies (compounder) | Micron (cyclical) |
|---|---|---|
| Sales growth | 12.1% a year, steady | 17.1% a year, but highly variable across years |
| Return on invested capital | 25.8%, stable | 27.7%, currently at the memory cycle peak |
| Valuation (P/FCF) | 15.7x, a reliable direct reading | 45.0x, to interpret based on where we are in the cycle |
| Free cash flow history | Positive and growing every year | Has turned negative during memory cycle troughs |
How my method adapts, without changing criteria
I keep the same ten criteria for everyone: profitability, sales and cash growth, buybacks, margins, debt, return on capital. What changes is how I use the result. On a compounder, I trust today's snapshot more to guess tomorrow. On a cyclical, I systematically look at the full five year history, including the troughs, not just the current peak, and ask myself where we likely stand in the cycle before judging valuation. A cyclical that keeps positive free cash flow even in its tough years, as Micron's history shows over time, deserves more credit than a cyclical that swings firmly negative every downturn.
What this changes for you in practice
When looking at a stock, first ask which family it belongs to. If its sales and cash grow almost every year without an obvious link to an external market factor, it's probably a compounder, and today's P/FCF is a good indicator. If its results depend heavily on a commodity price, a construction cycle, air travel, or electronic memory, it's a cyclical, and today's P/FCF needs to be placed within its cycle before drawing a conclusion. You can compare both profiles on <a href='/analyse/ROP'>the Roper Technologies analysis page</a> and <a href='/analyse/MU'>the Micron analysis page</a>, or explore <a href='/methodologie'>how I calculate the quality score and reasonable buy price</a> for any of the more than 5,000 stocks in my <a href='/screener'>screener</a>.
FAQ
What is a compounder stock?
It's a company that grows sales, cash, and profits steadily, year after year, with little dependence on an external market cycle. Roper Technologies is a good example.
What is a cyclical stock?
It's a company whose results depend heavily on a market cycle it doesn't control (a commodity price, a construction cycle, electronic memory). Its sales and cash can swing sharply from one year to the next, like Micron with the memory pricing cycle.
Why can P/FCF be misleading on a cyclical?
Because it's based on the past twelve months of cash. If the company is at the top of its cycle, that cash is artificially high, which can make the stock look cheap even though the cash could drop sharply once the cycle turns.
How do you know if a stock is cyclical or a compounder?
Look at five to ten years of history for its sales and free cash flow. If they grow almost every year without an obvious external link, it's a compounder. If they clearly follow a market cycle, sometimes turning negative, it's a cyclical.
Can a cyclical still be a good investment?
Yes, as long as you know where you stand in the cycle and don't judge its valuation on a single peak year of cash. A cyclical that keeps positive cash even in its troughs, as Micron has done before, deserves more credit than one that turns clearly negative every downturn.
Analyze a stock on Lubin Investment
About the author
Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).